

Technology Advisory Committee D Interests Register

Topic [ID3834]

Publication Date: 24/07/2024

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------------------------|------------------|-------------------------------------|--|--------------------------|--|
| Dr Scott Muir | Committee Member | Direct – Non-financial Professional | Dr Muir is Chairman of the Scottish Medicines Consortium and Chairman of the Glasgow and Clyde area Drugs and Therapeutics Committee | 19/09/2023 23/11/2023 | It was agreed that Dr Muir's declaration would not prevent him from participating in discussions on this appraisal |
| Giles Monnickendam | Committee Member | Direct - Financial | Giles has received honoraria and consulting fees from Janssen for advisory work in an unrelated indication (RR multiple myeloma) | 20/09/2023 | It was agreed that Giles' declaration would not prevent him from participating in discussions on this appraisal |
| David Meads | Committee Member | Non-financial Professional | The University of Leeds has received funding from Sanofi and Janssen for research in an unrelated area. | 26/09/2023 28/11/2023 | It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal |
| Professor Andrew Jones | Clinical Expert | Direct – non-financial | <ul style="list-style-type: none"> Andrew is a Member, NHS England Respiratory Medicine Clinical Reference Group Clinical 2016 – ongoing Member, NICE/NHSE Vertex CF modulator therapies Interim | 03/03/2023 | It was agreed that Andrew's declaration would not prevent him |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|-----------------|-----------------|-------------------------|--|-------------------------------------|--|
| | | Direct - financial | <p>Access Oversight Committee 2019-2022</p> <ul style="list-style-type: none"> Local site sub-investigator on Vertex clinical studies NICE Cystic Fibrosis Guideline Committee Member 2015-2017 (national CF clinical guideline), 2020 (CF COVID guideline) Until recently Andrew was a trustee of the Cystic Fibrosis Trust Andrew was a speaker at a recent CF academy meeting which was sponsored by Vertex and for which he received travel and speaker fees. In the past he has received an independent competitive investigator grant from Vertex | <p>12/10/2023</p> <p>14/12/2023</p> | from providing expert advice to the committee. |
| Andrew Lilley | Clinical Expert | Indirect - Professional | Andrew's trust and his department has been involved with Vertex but he has not personally been involved. | 12/10/2023 | It was agreed that Andrew's declaration would not prevent him from providing expert advice to the committee. |
| Dr Don Urquhart | Clinical Expert | | <ul style="list-style-type: none"> Dr Urquhart has previously received speaker fees from Vertex Pharmaceuticals | 10/08/2023 | It was agreed that Dr Urquhart's declaration would not prevent him |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|---------------|------------------|--------------------|---|-------------------|---|
| | | | <ul style="list-style-type: none"> Dr Urquhart has received fees for taking part in advisory boards for Vertex Pharmaceuticals and AbbVie Pharma. Dr Urquhart has been a principal investigator on a number of clinical trials undertaken by Vertex Pharmaceuticals | 14/12/2023 | from providing expert advice to the committee. |
| Will Sullivan | Committee Member | Direct – Financial | Roche products – Will's previous employer - was paid for him to provide consultancy advice to Hoffmann-La Roche AG, for a different product and different indication to those on the matrix list, in the last 12 months. | 27/11/2023 | It was agreed that Will's declaration would not prevent him from participating in discussions on this appraisal |